BlossomHill Therapeutics Names Jason Keyes CFO and EVP
09 May 2025 //
GLOBENEWSWIRE
BlossomHill Therapeutics to Present BH-30643 at 2025 AACR Meeting
03 Apr 2025 //
BUSINESSWIRE
BlossomHill Doses 1st Cohort in Ph 1/2 Trial for EGFR-HER2 NSCLC
22 Jan 2025 //
BUSINESSWIRE
BlossomHill Appoints Geoff Oxnard As CMO And EVP
06 Jan 2025 //
BUSINESSWIRE
BlossomHill Therapeutics Closes $100 Million Series B Financing
29 Feb 2024 //
BUSINESSWIRE